SAB Biotherapeutics warrant faces Nasdaq removal

SAB Biotherapeutics, Inc. is the issuer named in a Nasdaq notification to remove its warrant expiring October 22, 2026, from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934.

Rhea-AI Filing Summary

SAB Biotherapeutics, Inc. is the issuer named in a Nasdaq notification to remove its warrant expiring October 22, 2026, from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq states that it has reasonable grounds to believe it meets the requirements for filing the notification.

Key Figures

Warrant expiration: October 22, 2026

1 metrics

Warrant expiration October 22, 2026 Expiration date of the warrant class named in the notification

Key Terms

Section 12(b), Rule 12d2-2(b), voluntary withdrawal

3 terms

Section 12(b) regulatory

"under Section 12(b) of the Securities Exchange Act of 1934"

Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.

Rule 12d2-2(b) regulatory

"Pursuant to 17 CFR 240.12d2-2(b)"

voluntary withdrawal regulatory

"governing the voluntary withdrawal of the class of securities"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/22/2026 - 04:23 PM EDT Accepted by SEC EDGAR 10/22/2026 - 04:23 PM EDT Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

333-251178

Issuer:	SAB Biotherapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	777 West 41st St
	Suite 401
	Miami Beach	FLORIDA	33140
Telephone number:					(305) 204-3338

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Warrant expiring 10/22/2026

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-10-22	By	Jennifer Fainer		CDO Analyst
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.